Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.69 |
| ▸ | PARP2 | Q9UGN5 | 9/20 | 0.69 |
| ▸ | PARP3 | Q9Y6F1 | 9/20 | 0.69 |
| ▸ | TNKS | O95271 | 1/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.69 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.69 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.69 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.69 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.69 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.69 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.69 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16322554 | 1.00 | PARP1 (0.69) | PARP1PARP2PARP3TNKSCHRM2 | |
| Glycine SCHEMBL26133054 | 0.95 | PARP1 (0.64) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL16927695 | 0.89 | PARP1 (0.62) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL24301101 | 0.88 | PARP1 (0.69) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL21036416 | 0.88 | PARP1 (0.69) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL24235609 | 0.88 | PARP1 (0.69) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL24950168 | 0.86 | PARP1 (0.67) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL21155200 | 0.86 | PARP1 (0.67) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL26159121 | 0.86 | PARP1 (0.67) | PARP1PARP2PARP3TNKSCHRM2 | |
| SCHEMBL25938739 | 0.86 | PARP1 (0.67) | PARP1PARP2PARP3TNKSCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118414169-A | Transcyclooctene conjugates | 坦博公司 | 2024-07-30 | — | — | CN | disclosed |
| EP-3668857-B1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2023-07-05 | — | — | EP | disclosed |
| US-10927095-B2 | Processes for the preparation of Niraparib and intermediates thereof | TEVA PHARMACEUTICALS INTERNATIONAL GMBH | 2021-02-23 | — | — | US | disclosed |
| US-20200190056-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2020-06-18 | — | — | US | disclosed |
| EP-3536690-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | MSD Italia S.r.l. (IT) | 2019-09-11 | — | — | EP | disclosed |
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | disclosed |
| EP-2240466-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME (GB) | 2015-07-29 | — | — | EP | disclosed |
| EP-2805945-A1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD Italia S.r.l. (IT) | 2014-11-26 | — | — | EP | disclosed |
| US-8436185-B2 | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8071623-B2 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA | 2011-12-06 | — | — | US | disclosed |
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| EP-2240466-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | Merck Sharp & Dohme Limited (GB) | 2010-10-20 | — | — | EP | disclosed |
| EP-2109608-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2009-10-21 | — | — | EP | disclosed |
| WO-2009087381-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LTD (GB) | 2009-07-16 | — | — | WO | disclosed |
| WO-2008084261-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-10927095-B2 | Processes for the preparation of Niraparib and intermediates thereof | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885PARP3 3/4885 |
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | PARP1, PARP12, PARP15 | PARP1 1/4885PARP2 6/4885PARP3 7/4885 |
| US-20200190056-A1 | PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885PARP3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.